IDH1 and glioblastoma: Interestingly, under the same conditions applied to treat U-87 MG cells, Cyn inhibited the cell viability of patient-derived glioblastoma cell lines NULU and ZAR, known to be characterized by the wild-type IDH status and by an unmethylated MGMT gene promoter and, thus, by a TMZ-resistant phenotype.